PAD4 Inhibitor Compounds Selective Enzyme Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for peptidylarginine deiminases (PADs), particularly PAD4, which are associated with various diseases such as rheumatoid arthritis, systemic lupus erythematosus, and cancer, where citrullination and NETosis play a pathological role.
Innovation Solution
Development of novel compounds, specifically represented by Formula I and its derivatives, which act as inhibitors of PAD4 by contacting cells or administering them to patients to inhibit PAD4 activity and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for PAD-associated diseases, then existing therapeutic options are available, but effective inhibition of PAD4 activity is not achieved
Solution Approach 1:
The patent segments the therapeutic approach by developing specific compounds that selectively inhibit PAD4 isozyme while leaving other PAD isozymes unaffected. This is achieved through designing molecules with specific structural features (Formula I compounds) that target PAD4's active site with high selectivity, thereby providing reliable PAD4 inhibition without broad PAD enzyme suppression
Solution Approach 2:
The patent introduces small molecule compounds (Formula I and derivatives) as intermediary substances that mediate between the pathological process (PAD4-mediated citrullination and NETosis) and the desired therapeutic outcome. These compounds act as molecular intermediaries that bind to PAD4 and block its catalytic activity, thereby preventing downstream pathological effects in diseases like rheumatoid arthritis and lupus
2Reliability
If PAD4 inhibition is achieved through novel compounds, then therapeutic potential increases, but complexity of compound development and characterization increases
Solution Approach 1:
The patent systematically varies molecular parameters of the Formula I compounds, including substituent groups (R1-R17), ring structures, and side chains, to optimize PAD4 inhibition while maintaining manageable structural complexity. By methodically changing these chemical parameters and screening resulting compounds, the patent identifies optimal structures that balance therapeutic efficacy with structural tractability for synthesis and characterization
Data Source
AI summary
The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.